Hamza Hashmi

Wonderful opportunity sharing #BestofASCO 2025 highlights in Multiple Myeloma. How to (and not to) apply recent trial data in clinical practice. Some great talks on Leukemia, Lymphoma. #MMSM #CART #ASCODirect #ASCO25 #MedTwitter #MedEd @TotalHealthConf @ASCO @MSKCancerCenter

ASCO® 2025 Summary: Best of Myeloma-Key Trials & Clinical Insights | VuMedi vumedi.com/video/ascor-20… @vumedi ➡️Highlights, Summary, Take Home Messages ➡️Practice Changing vs Practice Informing @ASCO @oncodaily @MM_Hub @MSKCancerCente @ASHClinicalNews #MedTwitter #MedEd #ASCO25

This is a major win for patients . we have been advocating this with our publications on access ! Finally - REMS is revised and product labeling revision to include 2 weeks monitoring and driving restriction and not 4 weeks. 👍🏼 -monitor patients for at least 2 wk, with daily…

Proud to see our work finally out in #BloodICT @BloodPortfolio—thank you for the mentorship! It's been an incredible journey collaborating with the @MSKCancerCenter team these past years

#ComedyVsCancer @LincolnCenter in #NYC. Thank you @MSKCancerCenter for getting me the tix for this comedy event!! #ILoveComedy #Comedy #cancer #LetsCureCancer #LetsDoComedy #MMSM

🤣 Good for @Myeloma_Society for bringing out the puns already! Excited for #IMS25 🇨🇦 Cc @szusmani @Mohty_EBMT @JoshuaRichterMD @HiraSMian @EliasKarlMai @FrancescoMaura4 @SurbhiSidanaMD @UsuarezMD @JoselleCookMD @hhashmi87

Myeloma Paper of the Day, May 3rd, suggested by Robert Orlowski (@Myeloma_Doc) @MDAndersonNews @szusmani oncodaily.com/science/myelom… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #Myeloma #RRMM @CancerWorldmag

Are you ready for controversies in myeloma? Getting excited to discuss what happens beyond immunotherapy with ⁦@DottorClaudio⁩ ⁦@COMyCongress⁩ #mmsm ⁦@Mohty_EBMT⁩ comy.cme-congresses.com/program/

Looking forward to the inaugural #iwGPRC5D International Workshop on GPRC5D-Targeted Myeloma Therapies on March 22 in NYC! iwgprc5d.org/agenda/ Excited to learn & share our collective knowledge on the next frontier beyond BCMA. @szusmani @ShamMailankody @NoopurRajeMD ...

Can a signature be developed to predict relapse post CAR-T in multiple myeloma patients? Important question to be answered @hhashmi87 @szusmani #mmsm #tandem25 @MM_Hub @CIBMTR

Great job by @ABidikianMD presenting his first proposal at the @CIBMTR working committee meeting. Many more to come

This is a great one page/slide summary of possible remedies for Talq toxicities by @RahulBanerjeeMD Hopefully, change in dose/frequency & limited Rx duration will do the trick. #TimeLimitedTherapy #LessIsMore #MedTwitter

Thanks @vsanchorawala for leading @fredhutch Grand Rounds about AL amyloidosis 🙏 Lots of pearls, including importance both of early suspicion and accurate diagnosis. Patients can’t get better until we know the diagnosis… (Also the one scenario where 24-hr urines a must!)